Overview

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Treatments:
130-nm albumin-bound paclitaxel
Gemcitabine